Phase 1 trial supports safety and mechanism of action of peptide immunotherapy for peanut allergy.
Voskamp AL, Khosa S, Phan T, DeBerg HA, Bingham J, Hew M, Smith W, Abramovitch J, Rolland JM, Moyle M, Nadeau KC, Lack G, Larché M, Wambre E, O'Hehir RE, Hickey P, Prickett SR.
Voskamp AL, et al. Among authors: deberg ha.
Allergy. 2024 Feb;79(2):485-498. doi: 10.1111/all.15966. Epub 2023 Dec 19.
Allergy. 2024.
PMID: 38112286
Clinical Trial.